Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 18, 2005. The report primarily details changes in directors' interests in Ordinary Shares and the application for block listings of new shares on the London Stock Exchange.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and equity movements rather than financial performance.
Material Changes
- US Retirement Savings Plan Movements: The number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan fluctuated during the reporting period. On January 13, 2005, holdings decreased from 18,588,837 to 18,533,850 at an average price of $46.41. Subsequently, on January 14, 2005, holdings increased from 18,533,850 to 18,590,587 at an average price of $45.47.
- Directors' Notional Allocations: Following a re-valuation of the cash element within the US Retirement Savings Plan, notional allocations for Directors Dr J P Garnier and Dr T Yamada increased on January 14, 2005, at a price of $45.46 per share. Dr J P Garnier received an allocation of 77 shares, and Dr T Yamada received 12 shares.
- Block Listing Application: An application was made to the UK Listing Authority and the London Stock Exchange for block listings totaling 1,750,000 Ordinary shares of 25p each to be admitted to the Official List upon issuance.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a routine disclosure of share movements and listing applications.
Important Facts for Investor Verification
- Verification of the 1,750,000 new Ordinary shares application breakdown: 250,000 under the Savings Related Share Option Scheme, 500,000 under the SmithKline Beecham 1989 Executive Share Option Plan (Approved), and 1,000,000 under the SmithKline Beecham 1989 Executive Share Option Plan (US ADS Shareholders).
- Confirmation that the US Retirement Savings Plan is a discretionary fund where all employees and former employees are potential beneficiaries, creating potential indirect interests for Directors Dr J P Garnier and Dr T Yamada.
- Confirmation that the new shares will rank pari passu with existing issued shares of the Company.